Evidence map›Paper›PMID 29383520›Full record

Trial reportEuropean radiology2018

The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.

John M Hudson, Colleen Bailey, Mostafa Atri, Greg Stanisz, Laurent Milot, Ross Williams, Alex Kiss, Peter N Burns, Georg A Bjarnason

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05782400 (Multiomics Approach for Patients Stratification and Novel Target Identification in Metastatic Clear Renal Cell Carcnoma), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05782400 active not recruitingnot on this mapstarted 2023, after this paper: background citation

Multiomics Approach for Patients Stratification and Novel Target Identification in Metastatic Clear Renal Cell Carcnoma

TypeobservationalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2023 to 2027Enrolled100ConditionsMetastatic Clear Cell Renal CarcinomaArmsCT scan, Plasma collection
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Enhanced Diagnostic Imaging: Arrival-Time Parametric Imaging in Contrast-Enhanced Ultrasound for Multi-Organ Assessment.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John M HudsonDepartment of Medical Biophysics, University of Toronto, 2075 Bayview Ave, Room S6-39, Toronto, ON, M4N 3M5, Canada. john.hudson@mail.utoronto.ca.
Colleen BaileySunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Mostafa AtriDepartment of Medical Imaging, University of Toronto Health Network, Toronto, ON, Canada.
Greg StaniszDepartment of Medical Biophysics, University of Toronto, 2075 Bayview Ave, Room S6-39, Toronto, ON, M4N 3M5, Canada.
Laurent MilotDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ross WilliamsDepartment of Medical Biophysics, University of Toronto, 2075 Bayview Ave, Room S6-39, Toronto, ON, M4N 3M5, Canada.
Alex KissSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Peter N BurnsDepartment of Medical Biophysics, University of Toronto, 2075 Bayview Ave, Room S6-39, Toronto, ON, M4N 3M5, Canada.
Georg A BjarnasonDivision of Medical Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Room T2 049, Toronto, ON, M4N 3M5, Canada. georg.bjarnason@sunnybrook.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo identify dynamic contrast-enhanced (DCE) imaging parameters from MRI, CT and US that are prognostic and predictive in patients with metastatic renal cell cancer (mRCC) receiving sunitinib.

methodsThirty-four patients were monitored by DCE imaging on day 0 and 14 of the first course of sunitinib treatment. Additional scans were performed with DCE-US only (day 7 or 28 and 2 weeks after the treatment break). Perfusion parameters that demonstrated a significant correlation (Spearman p < 0.05) with progression-free survival (PFS) and overall survival (OS) were investigated using Cox proportional hazard models/ratios (HR) and Kaplan-Meier survival analysis.

resultsA higher baseline and day 14 value for Ktrans (DCE-MRI) and a lower pre-treatment vascular heterogeneity (DCE-US) were significantly associated with a longer PFS (HR, 0.62, 0.37 and 5.5, respectively). A larger per cent decrease in blood volume on day 14 (DCE-US) predicted a longer OS (HR, 1.45). We did not find significant correlations between any of the DCE-CT parameters and PFS/OS, unless a cut-off analysis was used.

conclusionsDCE-MRI, -CT and ultrasound produce complementary parameters that reflect the prognosis of patients receiving sunitinib for mRCC. Blood volume measured by DCE-US was the only parameter whose change during early anti-angiogenic therapy predicted for OS and PFS. KEY POINTS: • DCE-CT, -MRI and ultrasound are complementary modalities for monitoring anti-angiogenic therapy. • The change in blood volume measured by DCE-US was predictive of OS/PFS. • Baseline vascular heterogeneity by DCE-US has the strongest prognostic value for PFS.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBlood VolumeCarcinoma, Renal CellContrast MediaDisease-Free SurvivalDrug MonitoringFemaleHumansIndolesKaplan-Meier EstimateKidney NeoplasmsMagnetic Resonance ImagingMaleAntineoplastic AgentsContrast MediaIndolesPyrrolesSunitinibCarcinoma, Renal cellMagnetic resonance imagingPrognosisSunitinibTomography, X-Ray computed

Identifiers

PMID29383520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.